IL33 and Alzheimer disease: The proof-of-concept clinical trial showed a clinical improvement after a single intra- venous 300 mg dose of etokimab, with a humanized IgG1/kappa anti-IL-33 monoclonal antibody in 12 adult patients with moderate-to-severe AD [21].